Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

clear path for the resubmission of our NDA for NEBIDO(R), our commercial products are performing extremely well in their respective markets, our late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million financing this summer gives us a strong balance sheet.

"After receiving an Approvable letter in June from the FDA on our NDA for NEBIDO, we began planning the course toward resubmission to address FDA's concerns about the quantification of the incidence of serious cough reactions in clinical trials. The NDA contained a single, serious cough reaction in approximately 4,000 injections of NEBIDO. In September, we reached agreement with FDA that submitting additional safety data from ongoing clinical trials in Europe would be appropriate and sufficient to address their concerns. The new data include the results from approximately 10,000 additional injections in Phase IV trials conducted by our partner, Bayer Schering Pharma AG, Germany. The data from these trials has been collected and we believe that there have been no additional cases of serious cough reaction implying an incidence of approximately 1 in 14,000 injections which we believe confirms the rarity of the adverse event. We expect to re-file the NDA by the end of the first calendar quarter of 2009, and FDA will have six months to review the NDA.

"We continue to see strong performance and positive trends for VANTAS(R) (prostate cancer) and SUPPRELIN(R) LA (central precocious puberty). Sales of VANTAS units in the fourth quarter were up 70% over the fourth quarter last year, and we are encouraged by the trends in the first quarter. VANTAS is the only once-yearly treatment in the market and our sales force has done a terrific job of demonstrating the benefits of a long acting product," continued Dr. Cooper.

"Adoption of SUPPRELIN LA in the treatment of central precocious puberty continues
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... , Sept. 30, 2014  KemPharm, Inc., a ... and development of proprietary new molecular entity (NME) ... and Trademark Office (USPTO) issued U.S. Patent No. ... "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic ... and Use Thereof." The patent, which ...
(Date:9/30/2014)... 30, 2014 The custom stainless steel ... Product Show 2014. The Boston Area Chapter of ISPE ... annual, day-long event for Wed., Oct. 1 at Gillette ... be the largest in ISPE Boston’s long history, with ... 3,000 attendees expected. , HOLLOWAY AMERICA President David ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 UFP ... and specialty packaging has recently introduced a custom ... Suspension Pack . The new insulated shipper solves ... chain distribution process. UFP Technologies’ BioShell is a ... bags during storage, handling and shipping. The insulated ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... Corp ., a Madison biotechnology company, has raised $1 million ... the total raised to $3 million in the past two ... verify the efficacy of two products: adhesives that bind tissues ... and medical device coatings that block bacterial adhesion to the ...
... - Sir Ken Robinson has many ... his point about creativity than the story of a little ... a senior advisor to the J. Paul Getty Trust ... creativity and innovation, told the story during a keynote address ...
... 1995, I gave a luncheon speech to the Chicago Bar ... st Century." At that time, many who attended ... that much faith in it. My argument was that the ... maxed out. Municipalities would have to become more creative to ...
Cached Biology Technology:Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 2Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 3Creativity, innovation extend to municipalities 2Creativity, innovation extend to municipalities 3Creativity, innovation extend to municipalities 4
(Date:9/30/2014)... news release is available in German . ... are among the most expensive foods in the world. Because ... find them. But the distinctive smell of truffles is not ... French scientists under the direction of the Goethe University Frankfurt ... produced by soil bacteria which are trapped inside truffle fruiting ...
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... United States are changing and will face reduced growth ... this century, according to a study conducted by a ... of California, Santa Barbara; U.S. Geological Survey; and University ... Proceedings of the National Academy of Sciences ...
... It,s colds and flu season, and as any parent knows, ... New research using human-networking theory may give a clearer picture ... cold, influenza, whooping cough and SARS can spread through a ... With the help of 788 volunteers at a high ...
... ever, scientists have found a difference in the way males and ... that sexes likely use that difference to select their mates. ... team of researchers who found that male and female cichlid fishes ... as well. "It is difficult to say what colour ...
Cached Biology News:Drought and rising temperatures weaken southwest forests 2Human networking theory gives picture of infectious disease spread 2Human networking theory gives picture of infectious disease spread 3When it comes to selecting a mate, the eyes have it: Queen's University study 2
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
Biology Products: